Login / Signup

First-in-Human Study of OBI-999, a Globo H-Targeting Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors.

Apostolia-Maria TsimberidouHenry Hiep VoJennifer BeckChi-Sheng ShiaPei HsuTillman E Pearce
Published in: JCO precision oncology (2023)
The recommended phase II dose was determined to be 1.2 mg/kg once every 3 weeks. A phase II cohort-expansion study is now enrolling patients with pancreatic, colorectal, and other cancers expressing high levels of Globo H.
Keyphrases
  • phase ii
  • clinical trial
  • open label
  • endothelial cells
  • cancer therapy
  • phase iii
  • double blind
  • study protocol
  • placebo controlled